Loading
Life sciences · Journal article
Chemical & Biomedical Imaging · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract The extracellular matrix (ECM) secreted by cancer-associated fibroblasts (CAFs) impedes deep intratumoral infiltration of chemotherapeutic agents and immune cells, resulting in insufficient intratumoral drug accumulation and compromised antitumor efficacy. In this study, we engineered genetically bacterial minicell as a tumor microenvironment-responsive delivery platform to remodel CAFs and facilitate the deep intratumoral penetration of chemotherapeutics. Specifically, the carrier system was designed by encapsulating doxorubicin (DOX) within minicells functionalized with a matrix metalloproteinase 2 (MMP2)-cleavable melittin precursor fusion peptide, designated DOX@MCm. Upon exposure to elevated MMP2 levels in tumor tissue, active melittin is locally released, promoting DOX release while simultaneously enhancing its deep-tissue penetration by inhibiting CAF activation. In both standard and stroma-rich subcutaneous 4T1 tumor models, systemic DOX@MCm treatment significantly restrained primary tumor progression, ameliorated intratumoral fibrosis, elevated intratumoral cytotoxic CD8+ T cell populations, and exhibited minimal systemic toxicity, with no detectable organ injury or body weight loss. Furthermore, DOX@MCm markedly suppressed lung metastasis in stroma-rich subcutaneous 4T1 tumor models. Collectively, this MMP2-activatable melittin-engineered minicell delivery system achieves enhanced deep intratumoral penetration, stromal reprogramming, protease-triggered drug liberation and profoundly augmented antitumor immunity. The DOX@MCm establishes a biocompatible nanoplatform designed for synergistic therapy for stroma-rich solid tumors.